Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ConfiDisc secures USPTO key patent
The patent covers the innovator’s syringe injection system, which enables users to achieve the correct angle and depth of subcutaneous and intramuscular injections. The ConfiDisc syringe injection system,
The patent covers the innovator’s syringe injection system, which enables users to achieve the correct angle and depth of subcutaneous and intramuscular injections. The ConfiDisc syringe injection system,
Net income increased $5.1m from net loss of $2.2m for the year ended 31 May 2009 to net income of approximately $2.9m for the year ended 31 May
The Delhi High Court (HC) has rejected BMS’ plea for an interim injunction to temporarily stop Ranbaxy from producing and selling the drug in India. Justice Sunil Gaur
The collaboration is aimed at O-GIcNAcase, a target for Alzheimer’s, that modulates the solubility of the protein in these aggregates but that has been difficult to target with
The combined entity, called Valeant Pharmaceuticals International, will have a significantly expanded presence in North America and operations across eight other countries. The deal is expected to take
The new oxymorphone formulation is a semi-synthetic opioid analgesic intended for the treatment of moderate to severe chronic pain in patients requiring continuous, around-the-clock opioid treatment for an
The company claims that the Promus Element Stent features a novel platinum chromium alloy and stent design, which combine to offer greater radial strength and flexibility while reducing
The company claims that in the trial, the activity of PA401 was benchmarked against other relevant treatment modalities including the PDE4 inhibitor roflumilast and the CXCR2 antagonist SCH527123.
Miochol-E is an injectable miotic pharmaceutical used during certain eye surgeries to constrict the pupil. As per the agreement, Novartis will provide technical assistance to Bausch + Lomb
In 1999-2000, with an investment of $40m, Symphony Capital was the single largest shareholder, reported Financial Express. However, three years ago, Symphony’s stake in Orchid Chemicals was brought